ArriVent BioPharma, Inc. AVBP Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $62.1M+36.4% | $45.54M-59.6% | $112.67M-0.1% | $112.77M+126% | $49.87M-32.9% | ||
| $264.28M-1.1% | $267.28M+42.5% | $187.59M— | —— | —— | ||
| $77.81M+19.3% | $65.2M+22.5% | $53.24M+27.3% | $41.83M+12.4% | $37.21M-1.0% | ||
| $348.7M+4.7% | $332.9M+3.6% | $321.22M+28.4% | $250.15M+34.6% | $185.79M-18.1% | ||
| $370K+2,746% | $13K-73.5% | $49K-42.4% | $85K-29.2% | $120K-22.1% | ||
| $156K-17.9% | $190K+5.6% | $180K-62.4% | $479K+172% | $176K+39.7% | ||
| $349.3M+4.8% | $333.17M+2.0% | $326.56M+21.2% | $269.51M+25.1% | $215.5M-21.6% | ||
| $8.73M+47.1% | $5.93M0.0% | $5.93M+46.1% | $4.06M-7.0% | $4.36M+15.4% | ||
| $16.17M-19.1% | $20M+28.4% | $15.57M+0.6% | $15.48M+83.1% | $8.45M-36.6% | ||
| $99K+607% | $14K-75.0% | $56K-42.9% | $98K-29.0% | $138K-14.8% | ||
| $25M-3.7% | $25.95M+20.3% | $21.56M+9.8% | $19.64M+51.6% | $12.95M-25.0% | ||
| —— | —— | —— | —— | —— | ||
| $25.32M-2.4% | $25.95M+20.3% | $21.56M+9.8% | $19.64M+51.6% | $12.95M-25.1% | ||
| $5K+25.0% | $4K0.0% | $4K0.0% | $4K0.0% | $4K+33.3% | ||
| $772.21M+8.5% | $711.85M+5.6% | $673.88M+15.4% | $584M+15.6% | $505.28M+1.8% | ||
| -$447.96M-10.7% | -$404.64M-9.6% | -$369.1M-10.5% | -$334.12M-10.4% | -$302.72M-27.0% | ||
| -$270K-2,029% | $14K-93.2% | $206K— | —— | —— | ||
| $323.98M+5.5% | $307.22M+0.7% | $305M+22.1% | $249.87M+23.4% | $202.54M-21.4% | ||
| $349.3M+4.8% | $333.17M+2.0% | $326.56M+21.2% | $269.51M+25.1% | $215.5M-21.6% | ||
| $156K-17.9% | $190K+5.6% | $180K-62.4% | $479K+172% | $176K+39.7% | ||
| $370K+2,746% | $13K-73.5% | $49K-42.4% | $85K-29.2% | $120K-22.1% | ||
| —— | —— | —— | —— | —— | ||
| $370K+2,746% | $13K-73.5% | $49K-42.4% | $85K-29.2% | $120K-22.1% | ||
| $156K-17.9% | $190K+5.6% | $180K-62.4% | $479K+172% | $176K+39.7% | ||
| $264.28M-1.1% | $267.28M+42.5% | $187.59M— | —— | —— | ||
| $370K+2,746% | $13K-73.5% | $49K-42.4% | $85K-29.2% | $120K-22.1% | ||
| $156K-17.9% | $190K+5.6% | $180K-62.4% | $479K+172% | $176K+39.7% | ||
| $16.17M-19.1% | $20M+28.4% | $15.57M+0.6% | $15.48M+83.1% | $8.45M-36.6% | ||
| $16.17M-19.1% | $20M+28.4% | $15.57M+0.6% | $15.48M+83.1% | $8.45M-36.6% | ||
| $419K+2,893% | $14K-75.0% | $56K-42.9% | $98K-29.0% | $138K-21.6% | ||
| $5K+25.0% | $4K0.0% | $4K0.0% | $4K0.0% | $4K+33.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ArriVent BioPharma, Inc.'s total assets?
- ArriVent BioPharma, Inc. (AVBP) holds $349.3M in total assets, up 62.1% year over year.
- How much debt does ArriVent BioPharma, Inc. have?
- ArriVent BioPharma, Inc. carries $419.0K in total debt against $324.0M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does ArriVent BioPharma, Inc. have?
- ArriVent BioPharma, Inc. holds $62.1M in cash and equivalents.
- Can ArriVent BioPharma, Inc. cover its short-term obligations?
- Its current ratio is 13.95 — current assets exceed current liabilities.
- Where does ArriVent BioPharma, Inc.'s balance sheet data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.